Enlivex Therapeutics (NASDAQ:ENLV) Shares Up 1.9% – What’s Next?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares traded up 1.9% on Wednesday . The stock traded as high as $1.14 and last traded at $1.10. 53,853 shares changed hands during trading, a decline of 23% from the average session volume of 70,350 shares. The stock had previously closed at $1.08.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reissued a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a report on Friday.

Enlivex Therapeutics Trading Up 6.8 %

The firm has a market cap of $23.55 million, a PE ratio of -1.12 and a beta of 0.99. The firm has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $1.29.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its quarterly earnings results on Friday, November 29th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Equities analysts expect that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current fiscal year.

Institutional Trading of Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned approximately 0.14% of Enlivex Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.